TherapeuticsMD Inc (NASDAQ:TXMD) – Equities research analysts at Cantor Fitzgerald issued their FY2019 earnings per share estimates for TherapeuticsMD in a research note issued on Wednesday. Cantor Fitzgerald analyst W. Tanner anticipates that the company will post earnings per share of $0.24 for the year. Cantor Fitzgerald has a “Buy” rating and a $28.00 price objective on the stock.
Other research analysts have also issued reports about the stock. BidaskClub lowered shares of TherapeuticsMD from a “sell” rating to a “strong sell” rating in a report on Friday. Noble Financial restated a “buy” rating on shares of TherapeuticsMD in a report on Thursday. Deutsche Bank set a $9.00 price objective on shares of TherapeuticsMD and gave the stock a “buy” rating in a report on Wednesday, December 20th. Oppenheimer set a $10.00 price objective on shares of TherapeuticsMD and gave the stock a “buy” rating in a report on Wednesday. Finally, Cowen restated an “outperform” rating and issued a $16.00 price objective (up from $13.00) on shares of TherapeuticsMD in a report on Monday, November 6th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company. TherapeuticsMD presently has an average rating of “Buy” and an average target price of $14.50.
TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings data on Tuesday, February 20th. The company reported ($0.10) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.01). TherapeuticsMD had a negative return on equity of 65.30% and a negative net margin of 458.49%. The company had revenue of $4.13 million during the quarter, compared to the consensus estimate of $4.66 million. During the same quarter last year, the company posted ($0.12) earnings per share. The firm’s revenue for the quarter was down 8.0% compared to the same quarter last year.
In other TherapeuticsMD news, Director Tommy G. Thompson purchased 5,000 shares of the firm’s stock in a transaction that occurred on Friday, December 8th. The stock was bought at an average cost of $6.21 per share, for a total transaction of $31,050.00. Following the purchase, the director now directly owns 3,555 shares in the company, valued at $22,076.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 23.92% of the stock is owned by company insiders.
Several institutional investors have recently modified their holdings of the stock. MetLife Investment Advisors LLC bought a new position in shares of TherapeuticsMD in the 4th quarter worth about $423,000. Nexthera Capital LP bought a new position in shares of TherapeuticsMD in the 4th quarter worth about $3,191,000. Paloma Partners Management Co bought a new position in shares of TherapeuticsMD in the 4th quarter worth about $105,000. Ardsley Advisory Partners increased its stake in shares of TherapeuticsMD by 4,100.0% in the 4th quarter. Ardsley Advisory Partners now owns 1,050,000 shares of the company’s stock worth $6,342,000 after acquiring an additional 1,025,000 shares in the last quarter. Finally, California State Teachers Retirement System increased its stake in shares of TherapeuticsMD by 4.5% in the 4th quarter. California State Teachers Retirement System now owns 261,142 shares of the company’s stock worth $1,577,000 after acquiring an additional 11,317 shares in the last quarter. Institutional investors own 71.40% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This report was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.com-unik.info/2018/02/24/therapeuticsmd-inc-txmd-to-post-fy2019-earnings-of-0-24-per-share-cantor-fitzgerald-forecasts.html.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.